<DOC>
	<DOC>NCT00995449</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had an inadequate prior treatment outcome from biologic therapy.</brief_summary>
	<brief_title>Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>At least 6 swollen and at least 6 tender joints Creactive Protein (CRP) &gt; Upper Limit Normal (ULN) Prior inadequate response from biologic therapy Stable regimens of concomitant RA therapies Unstable medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Biologics-Inadequate</keyword>
	<keyword>KB003</keyword>
	<keyword>GM-CSF</keyword>
</DOC>